Silence Therapeutics PLC Result of AGM (2062H)

TIDMSLN

RNS Number : 2062H

Silence Therapeutics PLC

06 June 2017

Results of AGM

6 June 2017

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that all of the resolutions proposed at the Annual General Meeting were duly passed.

Enquiries:

 
 Silence Therapeutics plc                  Tel: +44 (0)20 
  Ali Mortazavi, Chief Executive Officer    3457 6900 
  David Ellam, Chief Financial Officer 
 Canaccord Genuity Limited (Nominated      Tel: +44 (0)20 
  Adviser and Joint Broker)                 7523 8350 
  Henry Fitzgerald-O'Connor/Emma Gabriel 
 Peel Hunt LLP (Joint Broker)              Tel: +44 (0)20 
  James Steel/Oliver Jackson                7418 8900 
 Media Enquiries:                          Tel: +44 (0) 
  FTI Consulting                            20 3727 1000 
  Simon Conway/Brett Pollard/Stephanie 
  Cuthbert 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGSSLEFIFWSEFM

(END) Dow Jones Newswires

June 06, 2017 02:01 ET (06:01 GMT)